<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/58724">
      <dc:title>Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma</dc:title>
      <dc:creator>Miguel-Pérez, Diego de</dc:creator>
      <dc:creator>Bayarri Lara, Clara Isabel</dc:creator>
      <dc:creator>Ortega, Francisco G.</dc:creator>
      <dc:creator>Russo, Alessandro</dc:creator>
      <dc:creator>Moyano Rodríguez, María José</dc:creator>
      <dc:creator>Álvarez Cubero, María Jesús</dc:creator>
      <dc:creator>Maza Serrano, Elizabeth</dc:creator>
      <dc:creator>Lorente Acosta, José Antonio</dc:creator>
      <dc:creator>Rolfo, Christian</dc:creator>
      <dc:creator>Serrano, María José</dc:creator>
      <dc:subject>Circulating tumor cells</dc:subject>
      <dc:subject>Adenocarcinoma</dc:subject>
      <dc:subject>Liquid biopsy</dc:subject>
      <dc:subject>NSCLC</dc:subject>
      <dc:subject>AXL</dc:subject>
      <dc:subject>Prognosis</dc:subject>
      <dc:description>Background: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite&#xd;
disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an urgent&#xd;
need to identify novel prognostic and predictive biomarkers. Lung adenocarcinoma has distinct&#xd;
clinical–pathological characteristics and novel therapeutic strategies are under active evaluation&#xd;
in the adjuvant setting. Here, we investigated the prognostic impact of circulating tumor cells&#xd;
(CTCs) and gene and miRNA tissue expression in resectable NSCLC. Results: ADC (n = 47) and SCC (n = 50) revealed&#xd;
different tissue expression profiles, resulting in the presence of different CTC subpopulations. In ADC,&#xd;
miR-155 correlated with AXL and IL6R expression, which were related to the presence of EMT CTC1&#xd;
(p = 0.014 and p = 0.004). In the multivariate analysis, CTC2 was an independent prognostic factor&#xd;
for relapse-free survival, and CTC3 and AXL were independent prognostic for overall survival only&#xd;
in ADC. Neither the surgery nor the adjuvant treatment influenced the prognosis of these patients.&#xd;
Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of&#xd;
CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation&#xd;
could potentially represent biomarkers for the stratification of ADC patients that might benefit from&#xd;
new adjuvant therapies.</dc:description>
      <dc:date>2020-01-14T11:21:26Z</dc:date>
      <dc:date>2020-01-14T11:21:26Z</dc:date>
      <dc:date>2019-11-07</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>de Miguel-Pérez, D., Bayarri-Lara, C. I., Ortega, F. G., Russo, A., Moyano Rodriguez, M. J., Alvarez-Cubero, M. J., ... &amp; Serrano, M. J. (2019). Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. Cancers, 11(11), 1750.</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/58724</dc:identifier>
      <dc:identifier>10.3390/cancers11111750</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>